VenoStent Analysis: $535K Raised
What is VenoStent?
VenoStent develops bioengineered vascular support technology, focusing on the SelfWrap, a bioabsorbable wrap to enhance dialysis access outcomes and minimize site failures.
Employees
17
Founded
2017
Revenue
$1.7M
Business Model
Subscription-based revenue model with monthly recurring revenue growth.
Product Features & Capabilities
- SelfWrap, bioabsorbable vascular wrap, flexible design, reduces dialysis access site failures
How much VenoStent raised
1: - $535,000
June 24, 2020Lead Investor: Not specified in the source.
Who are the founders of VenoStent
TB
Tim Boire
President and CEO
GL
Geoffrey Lucks
Co-founder & COO
Investors
- Norwest Venture Partners
- Good Growth Capital
- IAG Capital Partners
Market Focus
VenoStent primarily focuses on the medical technology industry, specifically developing bioengineered vascular support solutions for vascular surgery, with an emphasis on renal dialysis access.
Competitors Overview
VenoStent's main competitors in the vascular support solutions market, particularly for renal dialysis access, include:
- Invizius:
- Overview: Invizius is a clinical-stage biotechnology company focused on developing therapies to address complications associated with hemodialysis. Their
See something that needs updating? Suggest edits to this profile.